Fig. 2From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapyDistribution of the TNBCtype, PAM50, and PAM50 + Claudin-low subtypes within 350 clinically-defined TNBCsBack to article page